Purchasing Usifroid will give Telstar an 80 per cent share of the pharma freeze drying market in France, according to the company, and consolidate its position in Europe.
Telstar will also gain access to France-based Usifroid’s technology and expertise. Usifroid develops and supplies a range of good manufacturing practice (GMP) lyophilisation equipment, including systems using liquid nitrogen refrigeration technology in freeze drying.
Acquisition of these capabilities will strengthen Telstar’s offering. The Spain-based business provides technology in the fields of clean-air, sterilisation and water treatment, loading and unloading and freeze drying.
Telstar intends to retain the Usifroid brand and product range in all markets. Usifroid will continue to develop new equipment for the French and international markets and distribute the products under its existing brand name.
Furthermore, Telstar has indicated that it will provide financial backing for Usifroid and support its international activity, which is important for the company’s development, according to Benoit d’Armancourt, general manager of Usifroid.
d’Armancourt explained that Usifroid has always needed support to develop its activities and Telstar will provide this, as well understanding and experience of the requirements needed to operate in the life sciences equipment market.
Jordi Puig, corporate business director of Telstar, added that the acquisition will expand the company’s international activities. Telstar operates in more than 100 countries and has production plants in Spain, China, the US, UK, Holland, Germany and France.